Bill Text: IA HF2384 | 2015-2016 | 86th General Assembly | Introduced

---

Bill Title: A bill for an act relating to the medical cannabidiol Act, making related modifications, and providing for civil and criminal penalties and fees. (Formerly HSB 607)

Sponsorship: Committee Bill

Status: (Introduced - Dead) 2016-04-25 - Rereferred to Public Safety. H.J. 751. [HF2384 Detail]

Download: Iowa-2015-HF2384-Introduced.html

---

House File 2384 - Introduced




                                 HOUSE FILE       
                                 BY  COMMITTEE ON COMMERCE

                                 (SUCCESSOR TO HSB 607)

                                      A BILL FOR

  1 An Act relating to the medical cannabidiol Act, making
  2    related modifications, and providing for civil and criminal
  3    penalties and fees.
  4 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
    TLSB 6011HV (4) 86
    rh/rj

PAG LIN



  1  1    Section 1.  Section 124D.2, Code 2016, is amended by striking
  1  2 the section and inserting in lieu thereof the following:
  1  3    124D.2  Definitions.
  1  4    As used in this chapter:
  1  5    1.  "Cannabidiol" means a nonpsychoactive cannabinoid found
  1  6 in the plant Cannabis sativa L. or Cannabis indica or any
  1  7 other preparation thereof that is essentially free from plant
  1  8 material, and has a tetrahydrocannabinol level of no more than
  1  9 three percent.
  1 10    2.  "Debilitating medical condition" means any of the
  1 11 following:
  1 12    a.  Intractable epilepsy.
  1 13    b.  Multiple sclerosis.
  1 14    c.  Cancer, if a health care practitioner has determined a
  1 15 prognosis for a patient of less than twelve months of life.
  1 16    3.  "Department" means the department of public health.
  1 17    4.  "Health care practitioner" means an individual licensed
  1 18 under chapter 148 to practice medicine and surgery or
  1 19 osteopathic medicine and surgery who provides specialty care
  1 20 for a resident of this state for one or more debilitating
  1 21 medical conditions.
  1 22    5.  "Intractable epilepsy" means an epileptic seizure
  1 23 disorder for which standard medical treatment does not prevent
  1 24 or significantly ameliorate recurring, uncontrolled seizures or
  1 25 for which standard medical treatment results in harmful side
  1 26 effects.
  1 27    6.  "Medical cannabidiol manufacturer"  means an entity
  1 28 located in this state and licensed by the department to
  1 29 manufacture and to possess, cultivate, harvest, package,
  1 30 process, transport, supply, and dispense cannabidiol pursuant
  1 31 to the provisions of this chapter.
  1 32    7.  "Primary caregiver" means a person, at least eighteen
  1 33 years of age, who has been designated by a patient's health
  1 34 care practitioner or by a person having custody of a patient,
  1 35 as being necessary to take responsibility for managing the
  2  1 well=being of the patient with respect to the medical use of
  2  2 cannabidiol pursuant to the provisions of this chapter.
  2  3    Sec. 2.  Section 124D.3, Code 2016, is amended to read as
  2  4 follows:
  2  5    124D.3  Neurologist Health care practitioner recommendation
  2  6 == medical use of cannabidiol.
  2  7    A neurologist health care practitioner who has examined
  2  8 and treated a patient suffering from intractable epilepsy a
  2  9 debilitating medical condition may provide but has no duty to
  2 10 provide a written recommendation for the patient's medical use
  2 11 of cannabidiol to treat or alleviate symptoms of intractable
  2 12 epilepsy the debilitating medical condition 
  2 13  if no other satisfactory alternative treatment options exist
  2 14 for the patient and all of the following conditions apply:
  2 15    1.  The patient is a permanent resident of this state.
  2 16    2.  A neurologist health care practitioner has treated
  2 17 the patient for intractable epilepsy a debilitating medical
  2 18 condition for at least six months. For purposes of this
  2 19 treatment period, and notwithstanding section 124D.2,
  2 20 subsection 4, treatment provided by a neurologist health care
  2 21 practitioner may include treatment by an out=of=state licensed
  2 22 neurologist health care practitioner in good standing.
  2 23    3.  The neurologist health care practitioner has tried
  2 24 alternative treatment options that have not alleviated the
  2 25 patient's symptoms.
  2 26    4.  The neurologist health care practitioner determines
  2 27 the risks of recommending the medical use of cannabidiol are
  2 28 reasonable in light of the potential benefit for the patient.
  2 29    5.  The neurologist health care practitioner maintains a
  2 30 patient treatment plan.
  2 31    Sec. 3.  Section 124D.4, subsection 1, paragraph c, Code
  2 32 2016, is amended to read as follows:
  2 33    c.  Requests the patient's neurologist health care
  2 34 practitioner to submit a written recommendation to the
  2 35 department signed by the neurologist health care practitioner
  3  1  that the patient may benefit from the medical use of
  3  2 cannabidiol pursuant to section 124D.3.
  3  3    Sec. 4.  Section 124D.4, subsection 1, paragraph d,
  3  4 subparagraph (3), Code 2016, is amended to read as follows:
  3  5    (3)  Full name, address, and telephone number of the
  3  6 patient's neurologist health care practitioner.
  3  7    Sec. 5.  Section 124D.4, subsection 1, Code 2016, is amended
  3  8 by adding the following new paragraph:
  3  9    NEW PARAGRAPH.  e.  Submits a cannabidiol registration card
  3 10 fee of one hundred dollars to the department.  If the patient
  3 11 attests to receiving social security disability benefits,
  3 12 supplemental security insurance benefits, or being enrolled in
  3 13 the medical assistance program, the fee shall be twenty=five
  3 14 dollars.
  3 15    Sec. 6.  Section 124D.4, subsection 3, paragraph b, Code
  3 16 2016, is amended to read as follows:
  3 17    b.  Requests a patient's neurologist health care practitioner
  3 18  to submit a written recommendation to the department signed by
  3 19 the neurologist health care practitioner that a patient in the
  3 20 primary caregiver's care may benefit from the medical use of
  3 21 cannabidiol pursuant to section 124D.3.
  3 22    Sec. 7.  Section 124D.4, subsection 3, paragraph c,
  3 23 subparagraph (4), Code 2016, is amended to read as follows:
  3 24    (4)  Full name, address, and telephone number of the
  3 25 patient's neurologist health care practitioner.
  3 26    Sec. 8.  Section 124D.5, subsection 1, paragraph b,
  3 27 subparagraph (1), Code 2016, is amended by adding the following
  3 28 new subparagraph division:
  3 29    NEW SUBPARAGRAPH DIVISION.  (c)  To authorized employees of
  3 30 a medical cannabidiol manufacturer, but only for the purpose
  3 31 of verifying that a person is lawfully in possession of a
  3 32 cannabidiol registration card issued pursuant to this chapter.
  3 33    Sec. 9.  Section 124D.5, subsection 2, Code 2016, is amended
  3 34 by striking the subsection and inserting in lieu thereof the
  3 35 following:
  4  1    2.  The department shall adopt rules pursuant to chapter
  4  2 17A to administer this chapter which shall include but not be
  4  3 limited to rules to do all of the following:
  4  4    a.  Govern the manner in which the department shall consider
  4  5 applications for new and renewal cannabidiol registration
  4  6 cards.
  4  7    b.  Establish requirements for the suspension and revocation
  4  8 of a cannabidiol registration card and a medical cannabidiol
  4  9 manufacturer license.
  4 10    c.  Establish requirements for the licensure of medical
  4 11 cannabidiol manufacturers and set forth procedures for medical
  4 12 cannabidiol manufacturers to obtain licenses.
  4 13    d.  Develop a dispensing system for medical cannabidiol
  4 14 manufacturers to dispense cannabidiol within this state that
  4 15 provides for all of the following:
  4 16    (1)  Medical cannabidiol manufacturers within this state
  4 17 housed on secured grounds.
  4 18    (2)  The dispensing of cannabidiol to patients and their
  4 19 primary caregivers in person to occur at medical cannabidiol
  4 20 manufacturer locations designated by the department.
  4 21    e.  Establish and collect annual fees from medical
  4 22 cannabidiol manufacturers to cover the costs associated with
  4 23 regulating and inspecting medical cannabidiol manufacturers.
  4 24    f.  Specify and implement procedures that address public
  4 25 safety including security procedures and product quality
  4 26 including measures to ensure contaminant=free cultivation of
  4 27 cannabidiol, safety, and appropriate labeling.
  4 28    g.  Establish and implement a real=time, statewide
  4 29 cannabidiol registry management sale tracking system that
  4 30 is available to medical cannabidiol manufacturers on a
  4 31 twenty=four=hour=day, seven=day=a=week basis for the purpose
  4 32 of verifying that a person is lawfully in possession of
  4 33 a cannabidiol registration card issued pursuant to this
  4 34 chapter and for tracking the date of the sale and quantity of
  4 35 cannabidiol purchased by a patient or a primary caregiver.
  5  1    h.  Establish and implement a cannabidiol inventory and
  5  2 delivery tracking system to track cannabidiol from production
  5  3 by a medical cannabidiol manufacturer through dispensing by a
  5  4 medical cannabidiol manufacturer.
  5  5    Sec. 10.  Section 124D.6, subsections 1 and 2, Code 2016, are
  5  6 amended to read as follows:
  5  7    1.  a.  A recommendation for the possession or use of
  5  8 cannabidiol as authorized by this chapter shall be provided
  5  9 exclusively by a neurologist health care practitioner for a
  5 10 patient who has been diagnosed with intractable epilepsy a
  5 11 debilitating medical condition.
  5 12    b.  Cannabidiol provided exclusively pursuant to the
  5 13 recommendation of a neurologist shall be obtained from an
  5 14 out=of=state source and health care practitioner shall only be
  5 15 recommended for oral or transdermal administration.
  5 16    c.  A neurologist health care practitioner shall be the sole
  5 17 authorized recommender as part of the treatment plan by the
  5 18 neurologist health care practitioner of a patient diagnosed
  5 19 with intractable epilepsy a debilitating medical condition.
  5 20 A neurologist health care practitioner shall have the sole
  5 21 authority to recommend the use or amount of cannabidiol,
  5 22 if any, in the treatment plan of a patient diagnosed with
  5 23 intractable epilepsy a debilitating medical condition.
  5 24    2.  A neurologist health care practitioner, including
  5 25 any authorized agent thereof, shall not be subject to
  5 26 prosecution for the unlawful recommendation, possession, or
  5 27 administration of marijuana under the laws of this state for
  5 28 activities arising directly out of or directly related to
  5 29 the recommendation or use of cannabidiol in the treatment of
  5 30 a patient diagnosed with intractable epilepsy a debilitating
  5 31 medical condition.
  5 32    Sec. 11.  Section 124D.6, Code 2016, is amended by adding the
  5 33 following new subsection:
  5 34    NEW SUBSECTION.  2A.  A medical cannabidiol manufacturer,
  5 35 including any authorized agent or employee thereof, shall
  6  1 not be subject to prosecution for manufacturing, possessing,
  6  2 cultivating, harvesting, packaging, processing, transporting,
  6  3 supplying, or dispensing cannabidiol pursuant to this chapter.
  6  4    Sec. 12.  Section 124D.6, subsection 3, paragraphs a and b,
  6  5 Code 2016, are amended to read as follows:
  6  6    a.  In a prosecution for the unlawful possession of marijuana
  6  7 under the laws of this state, including but not limited to
  6  8 chapters 124 and 453B, it is an affirmative and complete
  6  9 defense to the prosecution that the patient has been diagnosed
  6 10 with intractable epilepsy a debilitating medical condition,
  6 11 used or possessed cannabidiol pursuant to a recommendation by a
  6 12 neurologist health care practitioner as authorized under this
  6 13 chapter, and, for a patient eighteen years of age or older, is
  6 14 in possession of a valid cannabidiol registration card.
  6 15    b.  In a prosecution for the unlawful possession of
  6 16 marijuana under the laws of this state, including but not
  6 17 limited to chapters 124 and 453B, it is an affirmative and
  6 18 complete defense to the prosecution that the person possessed
  6 19 cannabidiol because the person is a primary caregiver of a
  6 20 patient who has been diagnosed with intractable epilepsy a
  6 21 debilitating medical condition and is in possession of a
  6 22 valid cannabidiol registration card, and where the primary
  6 23 caregiver's possession of the cannabidiol is on behalf of the
  6 24 patient and for the patient's use only as authorized under this
  6 25 chapter.
  6 26    Sec. 13.  NEW SECTION.  124D.9  Medical cannabidiol
  6 27 manufacturer licensure.
  6 28    1.  The department shall license two medical cannabidiol
  6 29 manufacturers by December 1, 2016, to manufacture and dispense
  6 30 cannabidiol within this state consistent with the provisions
  6 31 of this chapter.  The department shall relicense the existing
  6 32 medical cannabidiol manufacturers by December 1 of each year.
  6 33    2.  As a condition for licensure, a medical cannabidiol
  6 34 manufacturer must agree to begin supplying and dispensing
  6 35 cannabidiol to patients in this state by July 1, 2017.
  7  1    3.  The department shall consider the following factors
  7  2 in determining whether to license a medical cannabidiol
  7  3 manufacturer:
  7  4    a.  The technical expertise of the medical cannabidiol
  7  5 manufacturer in cannabidiol.
  7  6    b.  The qualifications of the medical cannabidiol
  7  7 manufacturer's employees.
  7  8    c.  The long=term financial stability of the medical
  7  9 cannabidiol manufacturer.
  7 10    d.  The ability to provide appropriate security measures on
  7 11 the premises of the medical cannabidiol manufacturer.
  7 12    e.  The medical cannabidiol manufacturer's projection of
  7 13 and ongoing assessment of fees on patients with debilitating
  7 14 medical conditions.
  7 15    4.  The department shall require each medical cannabidiol
  7 16 manufacturer to contract with the state hygienic laboratory at
  7 17 the university of Iowa in Iowa City to test the cannabidiol
  7 18 produced by the medical cannabidiol manufacturer as to
  7 19 content, contamination, and consistency.  The department shall
  7 20 require that the laboratory report testing results to the
  7 21 medical cannabidiol manufacturer in a manner determined by the
  7 22 department pursuant to rule.
  7 23    5.  Each entity submitting an application for licensure as
  7 24 a medical cannabidiol manufacturer shall pay a nonrefundable
  7 25 application fee of ten thousand dollars to the department.
  7 26    Sec. 14.  NEW SECTION.  124D.10  Medical cannabidiol
  7 27 manufacturers.
  7 28    1.  A medical cannabidiol manufacturer shall pay the cost of
  7 29 all laboratory testing.
  7 30    2.  The operating documents of a medical cannabidiol
  7 31 manufacturer shall include all of the following:
  7 32    a.  Procedures for the oversight of the medical cannabidiol
  7 33 manufacturer and procedures to ensure accurate recordkeeping.
  7 34    b.  Procedures for the implementation of appropriate security
  7 35 measures to deter and prevent the theft of cannabidiol and
  8  1 unauthorized entrance into areas containing cannabidiol.
  8  2    3.  A medical cannabidiol manufacturer shall implement
  8  3 security requirements, including requirements for protection
  8  4 of each location by a fully operational security alarm system,
  8  5 facility access controls, perimeter intrusion detection
  8  6 systems, and a personnel identification system.
  8  7    4.  A medical cannabidiol manufacturer shall not share
  8  8 office space with, refer patients to, or have any financial
  8  9 relationship with a health care practitioner.
  8 10    5.  A medical cannabidiol manufacturer shall not permit any
  8 11 person to consume cannabidiol on the property of the medical
  8 12 cannabidiol manufacturer.
  8 13    6.  A medical cannabidiol manufacturer is subject to
  8 14 reasonable inspection by the department.
  8 15    7.  A medical cannabidiol manufacturer shall not employ a
  8 16 person who is under twenty=one years of age or who has been
  8 17 convicted of a disqualifying felony offense. An employee
  8 18 of a medical cannabidiol manufacturer shall be subject to a
  8 19 background investigation  conducted by the division of criminal
  8 20 investigation of the department of public safety and a national
  8 21 criminal history background check.
  8 22    8.  A medical cannabidiol manufacturer shall comply with
  8 23 reasonable restrictions set by the department relating to
  8 24 signage, marketing, display, and advertising of cannabidiol.
  8 25    9.  a.  All manufacturing, cultivating, harvesting,
  8 26 packaging, and processing of cannabidiol shall take place in an
  8 27 enclosed, locked facility at a physical address provided to the
  8 28 department during the licensure process.
  8 29    b.  A medical cannabidiol manufacturer shall manufacture
  8 30 a reliable and ongoing supply of cannabidiol to treat every
  8 31 debilitating medical condition listed in this chapter.
  8 32    c.  A medical cannabidiol manufacturer shall not, within
  8 33 a thirty=day period, dispense more than thirty=two ounces of
  8 34 cannabidiol to a patient or a primary caregiver.
  8 35    10.  A medical cannabidiol manufacturer shall pay an
  9  1 annual fee determined by the department equal to the cost of
  9  2 regulating and inspecting the medical cannabidiol manufacturer
  9  3 during that year.
  9  4    Sec. 15.  NEW SECTION.  124D.11  Fees.
  9  5    Cannabidiol registration card fees and medical cannabidiol
  9  6 manufacturer application and annual fees collected by the
  9  7 department pursuant to this chapter shall be retained by
  9  8 the department, shall be considered repayment receipts as
  9  9 defined in section 8.2, and shall be used for the purpose of
  9 10 regulating medical cannabidiol manufacturers and for other
  9 11 expenses necessary for the administration of this chapter.
  9 12 Notwithstanding section 8.33, moneys that remain unencumbered
  9 13 or unobligated at the end of the fiscal year shall not revert
  9 14 to the general fund of the state.
  9 15    Sec. 16.  NEW SECTION.  124D.12  Use of cannabidiol ==== smoking
  9 16 and vaping prohibited.
  9 17    A patient shall not consume cannabidiol possessed or used as
  9 18 authorized by this chapter by smoking or vaping cannabidiol.
  9 19    Sec. 17.  NEW SECTION.  124D.13  Penalties.
  9 20    1.  A person who knowingly or intentionally possesses or uses
  9 21 cannabidiol in violation of the requirements of this chapter is
  9 22 subject to the penalties provided under chapters 124 and 453B.
  9 23    2.  A medical cannabidiol manufacturer shall be assessed
  9 24 a civil penalty of up to one thousand dollars per violation
  9 25 for any violation of this chapter in addition to any other
  9 26 applicable penalties.
  9 27    Sec. 18.  REPEAL.  Sections 124D.7 and 124D.8, Code 2016,
  9 28 are repealed.
  9 29                           EXPLANATION
  9 30 The inclusion of this explanation does not constitute agreement with
  9 31 the explanation's substance by the members of the general assembly.
  9 32    This bill relates to the medical cannabidiol Act, makes
  9 33 related modifications, and provides for civil and criminal
  9 34 penalties and fees.
  9 35    MEDICAL CANNABIDIOL ACT == OVERVIEW.  Iowa Code chapter
 10  1 124D, the medical cannabidiol Act, currently allows an Iowa
 10  2 licensed neurologist who has examined and treated a patient
 10  3 suffering from intractable epilepsy to  provide a written
 10  4 recommendation for the patient's medical use of cannabidiol
 10  5 to treat or alleviate symptoms of intractable epilepsy if
 10  6 no other satisfactory alternative treatment options exist
 10  7 and if certain conditions apply.  A patient who receives a
 10  8 written recommendation from the patient's neurologist or
 10  9 the patient's primary caregiver is required to have a valid
 10 10 cannabidiol registration card to use or possess cannabidiol
 10 11 for medical purposes.  The cannabidiol must be obtained from
 10 12 an out=of=state source.  The department of public health
 10 13 is required to maintain a confidential file of the names
 10 14 of each patient and primary caregiver to or for whom the
 10 15 department issues a cannabidiol registration card and to keep
 10 16 such information confidential except as otherwise allowed.
 10 17 The medical cannabidiol Act provides affirmative defenses
 10 18 to a neurologist, a patient, and a primary caregiver from
 10 19 prosecution.  A person who knowingly or intentionally possesses
 10 20 or uses cannabidiol in violation of the medical cannabidiol
 10 21 Act is subject to the penalties provided under Code chapters
 10 22 124 (controlled substances) and 453B (excise taxes on unlawful
 10 23 dealing in certain substances).
 10 24    DEBILITATING MEDICAL CONDITIONS == HEALTH CARE PRACTITIONER.
 10 25  The bill amends the medical cannabidiol Act to include multiple
 10 26 sclerosis and terminal cancer, in addition to intractable
 10 27 epilepsy, as additional debilitating medical conditions for
 10 28 which a patient may receive a written recommendation from a
 10 29 health care practitioner for the patient's medical use of
 10 30 cannabidiol. "Health care practitioner" is defined to mean any
 10 31 Iowa licensed physician who provides specialty care for one or
 10 32 more debilitating medical conditions.
 10 33    CANNABIDIOL REGISTRATION CARD FEE.  The bill requires a
 10 34 patient to submit a cannabidiol registration card fee of $100
 10 35 or $25 to the department, depending on whether a patient is the
 11  1 recipient of certain public assistance.
 11  2    CONFIDENTIALITY.  The bill provides that confidential
 11  3 patient and primary caregiver cannabidiol registration card
 11  4 information maintained by the department may be disclosed to
 11  5 authorized employees of a medical cannabidiol manufacturer
 11  6 under certain circumstances.
 11  7    MEDICAL CANNABIDIOL MANUFACTURER == LICENSURE.  The bill
 11  8 requires the department to license by December 1, 2016,
 11  9 two medical cannabidiol manufacturers to manufacture and
 11 10 dispense cannabidiol within this state. As a condition for
 11 11 licensure, a medical cannabidiol manufacturer must agree to
 11 12 begin supplying and dispensing cannabidiol to patients in
 11 13 this state by July 1, 2017. The department is directed to
 11 14 consider several factors in determining whether to license a
 11 15 medical cannabidiol manufacturer. Each medical cannabidiol
 11 16 manufacturer is required to contract with the state hygienic
 11 17 laboratory at the university of Iowa to test the cannabidiol
 11 18 produced by the manufacturer and to report testing results to
 11 19 the medical cannabidiol manufacturer, and is required to pay a
 11 20 nonrefundable application fee of $10,000.
 11 21    MEDICAL CANNABIDIOL MANUFACTURER == ADDITIONAL REQUIREMENTS.
 11 22  The bill provides that certain requirements must be included in
 11 23 the operating documents of a medical cannabidiol manufacturer.
 11 24 A medical cannabidiol manufacturer is prohibited from engaging
 11 25 in certain activities and is subject to reasonable inspection
 11 26 and reasonable restrictions by the department.
 11 27    A medical cannabidiol manufacturer is required to provide
 11 28 a reliable and ongoing supply of cannabidiol to treat every
 11 29 debilitating medical condition pursuant to the provisions of
 11 30 the bill and shall manufacture, cultivate, harvest, package,
 11 31 and process cannabidiol in an enclosed, locked facility at
 11 32 a physical address provided to the department during the
 11 33 licensure process.
 11 34    FEES.  Cannabidiol registration card fees and medical
 11 35 cannabidiol manufacturer application and annual fees collected
 12  1 by the department shall be retained by the department, and
 12  2 shall be used for the purpose of regulating medical cannabidiol
 12  3 manufacturers and for other expenses necessary for the
 12  4 administration of the bill.
 12  5    ADDITIONAL DEPARTMENT DUTIES ==== RULES.  The bill requires
 12  6 the department to adopt rules relating to cannabidiol
 12  7 registration cards and medical cannabidiol manufacturer
 12  8 licenses, requirements for the licensure of medical cannabidiol
 12  9 manufacturers, a dispensing system for medical cannabidiol
 12 10 manufacturers to dispense cannabidiol within this state
 12 11 that follows certain requirements, annual fees from medical
 12 12 cannabidiol manufacturers, public safety procedures, and the
 12 13 establishment and implementation of a statewide cannabidiol
 12 14 registry management sale tracking system.
 12 15    USE OF CANNABIDIOL ==== SMOKING AND VAPING PROHIBITED.  The
 12 16 bill provides that a patient, including an out=of=state patient
 12 17 who is in Iowa, shall not consume the cannabidiol by smoking or
 12 18 vaping the cannabidiol.
 12 19    USE OF MEDICAL CANNABIDIOL ==== AFFIRMATIVE DEFENSES.
 12 20  The bill provides prosecution immunity for a health care
 12 21 practitioner and a medical cannabidiol manufacturer
 12 22 including any authorized agents or employees of the health
 12 23 care practitioner or medical cannabidiol manufacturer, for
 12 24 activities undertaken by the health care practitioner or
 12 25 medical cannabidiol manufacturer, pursuant to the provisions
 12 26 of the bill.
 12 27    PENALTIES.  The bill provides that a medical cannabidiol
 12 28 manufacturer shall be assessed a civil penalty of up to $1,000
 12 29 per violation for any violation of the bill in addition to any
 12 30 other applicable penalties.
 12 31    REPEAL.  The bill repeals Code sections 124D.7 (penalties)
 12 32 and 124D.8 (repealing Code chapter 124D on July 1, 2017).
       LSB 6011HV (4) 86
       rh/rj